BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11038763)

  • 1. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
    Li D; Li G; Wang B
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
    Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
    Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
    Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
    Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma].
    Zhang DS; Jiang WQ; Li S; Zhang XS; Mao H; Chen XQ; Li YH; Zhan J; Wang FH
    Ai Zheng; 2003 Aug; 22(8):870-3. PubMed ID: 12917038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Measurement of five cytokines in the serum of malignant lymphoma patients].
    Zhu H; Wang Y; Han X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
    Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
    Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma.
    Stasi R; Stipa E; Masi M; Oliva F; Sciarra A; Perrotti A; Zaccari G; Papa G
    Thromb Haemost; 1993 Oct; 70(4):568-72. PubMed ID: 8115979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-alpha induces changes in LDH isotype profile following triggering of apoptosis in PBL of non-Hodgkin's lymphomas.
    Jurisic V; Bumbasirevic V; Konjevic G; Djuricic B; Spuzic I
    Ann Hematol; 2004 Feb; 83(2):84-91. PubMed ID: 14586559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95.
    Seidemann K; Zimmermann M; Book M; Meyer U; Burkhardt B; Welte K; Reiter A; Stanulla M
    J Clin Oncol; 2005 Nov; 23(33):8414-21. PubMed ID: 16293872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.
    Voorzanger N; Touitou R; Garcia E; Delecluse HJ; Rousset F; Joab I; Favrot MC; Blay JY
    Cancer Res; 1996 Dec; 56(23):5499-505. PubMed ID: 8968107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
    Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
    Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
    Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
    Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes of proinflammatory cytokines and their receptors in serum from patients with pulmonary tuberculosis].
    Tang S; Xiao H; Fan Y; Wu F; Zhang Z; Li H; Yang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):325-9. PubMed ID: 12126553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
    Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
    Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
    Ozdemir F; Aydin F; Yilmaz M; Kavgaci H; Bektas O; Yavuz MN; Yavuz AA
    J Exp Clin Cancer Res; 2004 Sep; 23(3):485-8. PubMed ID: 15595640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.